endovion (SCO-101)

These findings highlight the therapeutic potential of SCO-101 in overcoming MDR by inhibiting drug efflux mechanisms and metabolism, thereby enhancing chemotherapy efficacy. SCO-101 is currently undergoing clinical trials as an orally administered drug and is considered a promising strategy for improving cancer treatment outcomes in patients with drug-resistant tumors.

However, no clear added efficacy signal was observed of the combination. Trial registration number: NCT04652205 (Nov 29, 2020).

Inhibition of SRPK1 with either of the compounds promotes transcription elongation, and transcriptionally activates the unfolded protein response. In brief, here we discover that CDK12 inactivation promotes MYC signaling in an SRPK1-dependent manner, and show that the clinical grade compound Endovion selectively targets the cells with CDK12 inactivation.

SCO-101 is a compound for oral use that was shown to revert drug resistance in preclinical studies: In taxane-resistant cancer cells SCO-101 resensitized tumor cells to taxane and reduced the active efflux of ATP Binding Cassette G2 substrate molecules from irinotecan resistant colon cancer cells. DLTs were observed in 2 pts in the cohort treated with 250mg of SCO-101, hence MTD for SCO-101 concurrent with Gem-Nab was determined to be 200mg once daily for 6 days on a bi-weekly schedule. A full description of toxicities is pending.

P2, N=35, Recruiting, Scandion Oncology A/S | Trial completion date: Mar 2021 --> Jun 2022 | Trial primary completion date: Jan 2021 --> Jun 2022

P2, N=35, Recruiting, Scandion Oncology A/S | Not yet recruiting --> Recruiting

P2, N=35, Not yet recruiting, Scandion Oncology A/S | Trial completion date: Sep 2021 --> Mar 2021 | Trial primary completion date: May 2021 --> Jan 2021

P2, N=35, Not yet recruiting, Scandion Oncology A/S